ReviewExperimental & molecular medicine2026
Single-cell epigenomics of colorectal cancer.
Review in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Colorectal cancer (CRC) exhibits remarkable phenotypic heterogeneity that cannot be fully explained by genetic alterations alone. Advances in single-nucleus assay for transposase-accessible chromatin sequencing have revealed chromatin accessibility as a central regulatory layer shaping tumor identity, cellular plasticity and therapeutic response. In this Review, we synthesize recent single-cell epigenomic studies to outline an emerging regulatory principle for CRC. From an epigenetic perspective, CRC can be conceptualized as two distinct epigenomic states, intrinsic consensus molecular subtype (iCMS)2 and iCMS3, defined by divergent cis-regulatory element activities across distal enhancer and promoter landscapes. Tumor progression is accompanied by stepwise regulatory rewiring, encompassing erosion of differentiation programs in adenomas, regulatory bifurcation during malignant transformation, oncofetal reprogramming associated with therapy resistance and organotropic adaptation during metastasis. We further discuss how stromal and immune compartments undergo dynamic epigenomic remodeling, converging toward a concept of iCMS-defined epigenomic ecosystems, and how genomic alterations engage in bidirectional crosstalk with chromatin states to generate intratumoral heterogeneity. Finally, we highlight translational applications including epigenetic-immune combination therapies, liquid biopsy-based monitoring, spatial epigenomics and artificial intelligence-driven modeling.
Identifiers
42827107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.